Xenon Pharmaceuticals, Inc.
http://www.xenon-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xenon Pharmaceuticals, Inc.
Unpartnered Assets To Watch In 2024
Licensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months.
Finance Watch: Stark Contrast As Big FOPOs Reach Market, Other Firms Cut Costs
Public Company Edition: Arvinas grossed $350m in a private placement, while Xenon brought in $345m and Pharvaris raised $300m in follow-on public offerings. Fundraising remains challenging, however, so IGM Biosciences, Hansa Biopharma and other companies cut costs to save money.
Neurocrine Seizure Drug Failure Draws Concern For Additional Program
The company said two Phase II programs – NBI-921352 in focal onset seizure and NBI-1065846 in anhedonia – failed. It is investigating potential read-through to another seizure disorder for ‘352.
How To Turn Around A Struggling Biotech
Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice